Synchron files the first premarket approval (PMA) application with the FDA for a permanently implanted BCI, the Stentrode, by the end of 2027.
Will Synchron Submit a PMA Application for Stentrode by the End of 2027?
Synchron, a leading developer of brain-computer interfaces (BCIs), is expected to submit a Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Stentrode device by the end of 2027. Based on recent funding rounds and clinical progress, the probability of this submission is estimated at 60%. The company has raised significant capital to accelerate its regulatory pathway, and early trial results are promising.
What Is the Stentrode BCI and How Does It Differ from Other Implants?
The Stentrode is a minimally invasive brain-computer interface. Unlike traditional BCIs that require open brain surgery, the Stentrode is delivered via a catheter through the jugular vein to a blood vessel adjacent to the motor cortex. This approach avoids craniotomy, reducing procedural risk and potentially speeding up physician adoption. It leverages standard interventional techniques already used in millions of procedures.
What Are Synchron's Funding Milestones and How Do They Support the 2027 Goal?
In November 2025, Synchron announced a $200 million Series D round to fund its first pivotal trial, which began in 2026. In June 2026, the company closed a $275 million Series E round specifically to accelerate its PMA submission, targeting late 2027. As of mid-2026, Synchron has implanted the Stentrode in over 100 patients, making it one of the best-funded pure-play BCI companies.
What Does the COMMAND Pivotal Trial Data Show So Far?
The COMMAND trial is the pivotal study supporting the PMA application. Early data from patients with paralysis or ALS show stable signal quality over 12 to 18 months and typing speeds of 23 to 25 characters per minute. These results are encouraging, but final approval depends on the full dataset and FDA's acceptance of the trial protocol.
What Are the Key Risks to the 2027 Submission Timeline?
The primary risk is regulatory delay. The FDA's review speed and the timing of protocol acceptance can shift the submission date. Additionally, if any safety or efficacy issues arise in the pivotal trial, the timeline could be extended. Therefore, while the target is late 2027, the probability is moderate at 60%.
Frequently Asked Questions
Is the Stentrode approved by the FDA?
No, the Stentrode is not yet FDA approved. It is currently in clinical trials under an Investigational Device Exemption (IDE). Synchron plans to submit a PMA application by the end of 2027, but approval may come later.
How is the Stentrode implanted?
The Stentrode is implanted via a minimally invasive endovascular procedure. A catheter is inserted through the jugular vein and guided to a blood vessel near the motor cortex. The device expands to sit against the vessel wall, where it records brain signals without penetrating brain tissue.
What conditions could the Stentrode treat?
The Stentrode is designed to help people with severe paralysis, including those with ALS, stroke, or spinal cord injury. It enables them to control digital devices, such as typing on a computer or using a tablet, using their thoughts.
Sources
- Synchron Announces $200 Million Series D to Support Pivotal Trial (November 2025) - Synchron Closes $275 Million Series E to Accelerate Regulatory Submission (June 2026) - Synchron Reports Over 100 Implanted Patients and Early COMMAND Trial Data (Mid-2026)